Market Leader - Infectious Disease Diagnostics Market
The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2% during the forecast period. Growth in the infectious disease diagnostics industry is mainly driven by factors such as the rising prevalence of infectious diseases & onset of COVID-19 and the rising funding for R&D in infectious disease diagnostics. The growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized point-of-care testing and rising technological advancements are factors supporting the growth of this market. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
The major players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd(Switzerland), bioMérieux SA (France), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Quidel Corporation(US), Hologic, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), PerkinElmer Inc. (US), QIAGEN (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics (US), Luminex Corporation (US), Meridian Bioscience (US), Genetic Signatures (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems, Inc. (US), Seegene Inc. (South Korea), Co-Diagnostics, Inc. (US), ELITechGroup (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), and ABACUS Diagnostica Oy (Finland).
To know about the assumptions considered for the study download the pdf brochure
Abbott Laboratories accounted for the largest share of the infectious disease diagnostics market in 2020. Abbott Laboratories is a leading player in the infectious disease diagnostics market. The launch of the ID NOW POC testing system by the company is expected to support the growth of its infectious disease diagnostics segment. Abbott Laboratories operates through 291 international and 100 domestic subsidiaries and has a strong geographical presence.
F. Hoffmann-La Roche Ltd. accounted for the second largest share of the infectious disease diagnostics market in 2020. Under its flagship brand- cobas- the company offers a wide variety instruments and reagents that are widely used by end users across the globe. The company also has a wide geographic presence, spanning North America, Europe, the Middle East and Africa, and Asia. This enables the company to cater to customers across the globe. Roche Diagnostics mainly focuses on strategic partnerships & acquisitions to maintain its leading position in the market.
bioMérieux SA accounted for the third largest share of the infectious disease diagnostics market. The company operates in more than 150 countries across the Americas, Europe, the Middle East and Africa, and the Asia Pacific and has 18 production sites and 20 R&D sites. It has 43 subsidiaries across the globe. The company has a strong product portfolio which has helped it to maintain and enhance its presence in the infectious disease diagnostics market.
Related Reports:
Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User - Global Forecast to 2026
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment